An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX
Phase of Trial: Phase III
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Fitusiran (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Adverse reactions
- Acronyms ATLAS-OLE
- Sponsors Sanofi Genzyme
- 02 Oct 2019 Planned End Date changed from 1 Dec 2024 to 1 Oct 2025.
- 02 Oct 2019 Planned primary completion date changed from 1 Dec 2024 to 1 Oct 2025.
- 24 Jun 2019 Planned End Date changed from 1 Oct 2024 to 1 Dec 2024.